J&J's Erleada Approved By FDA In New Prostate Cancer Indication
Erleada was approved for treatment of metastatic castration-sensitive prostate cancer (mCSPC), strengthening its position versus generic Zytiga and Pfizer/Astellas's Xtandi.
You may also be interested in...
A strong fourth quarter and full-year 2019 performance by J&J was driven by significant sales growth for Tremfya and Stelara. CFO Wolk said a $4bn opioids settlement remains on track.
Erleada is ninth product known to be using US FDA’s Real-Time Oncology Review pilot program, as shown in our comprehensive chart.
Metastatic castration-sensitive prostate cancer could see a marketing race following positive top-line clinical data for Janssen’s apalutamide in the Phase III TITAN study.